Article Corrected

Spohn G, Geisen C, Luxembourg B, Sittinger K, Seifried E, Bönig H. Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics. Mol Diagn Ther 2011; 15 (1): 513-9

Corrections Made

Page 15, figure 1: In panel (b), the graphic showing the sequence and location of the forward primer was incorrect, and in panel (e), an incorrect gel image was shown. These graphics have now been replaced, and a corrected version of figure 1 is shown below:

Fig. 1. Primer location and representative genotyping results. (a–c) Locations of the primers for genotyping of (a) *VKORC1* –1639G>A, (b) *CYP2C9* 430C>T (*CYP2C9**2), and (c) *CYP2C9* 1075A>C (*CYP2C9**3). (d–f) Representative results for genotyping of six individuals each for (d) *VKORC1* –1639G>A, (e) *CYP2C9**2, and (f) *CYP2C9**3. Shown in each of the gel images (d–f), from left to right, are the molecular weight marker, 2 wild-type samples, 2 heterozygote variant samples, and 2 homozygous variant samples. The white block arrow indicates the internal control band, the gray block arrow indicates the wild-type band, and the black block arrow indicates the variant band. *CYP2C9* = cytochrome P450 2C9; *VKORC1* = vitamin K epoxide reductase complex subunit 1.

Page 16, table I, *CYP2C92 section, column 3:** In the first row, the sequence of the C2C9-E3-forward primer, which previously read:
“TAGTAACTTCGTTTGCTGTTATCTCTG”

has now been corrected as follows:

“AATAGTAACTTCGTTTGCTGTTATCTC”.

Page 16, table I, *CYP2C92 section, column 5:** In the first row, the final concentration of the C2C9-E3-forward primer, which previously read:

“0.2 (μM)”

has now been corrected as follows:

“0.24 (μM)”.

Page 16, table I, *CYP2C92 section, column 5:** In the second row, the final concentration of the C2C9-E3-reverse primer, which previously read:

“0.2 (μM)”

has now been corrected as follows:

“0.16 (μM)”.

Page 16, table I, *CYP2C92 section, column 5:** In the third row, the final concentration of the C2C9-E3-T-forward primer, which previously read:

“0.2 (μM)”

has now been corrected as follows:

“0.16 (μM)”.

Page 16, table I, *CYP2C92 section, column 5:** In the fourth row, the final concentration of the C2C9-E3-C-reverse primer, which previously read:

“0.2 (μM)”

has now been corrected as follows:

“0.24 (μM)”.

A corrected version of table I is shown below:

Table I. Primers used for duplex ASA-PCR of the *VKORC1* –1639G>A, *CYP2C9**2, and *CYP2C9**3 polymorphisms

Target	Primer	Sequence 5'–3'	Orientation	Final concentration (μM)
<i>VKORC1</i> –1639G>A	VKORC1-forward	AGTTCCAGGGATTTCATGCAG	Forward	0.16
	VKORC1-reverse	ATTGCCCTGACACCTAGTGG	Reverse	0.24
	VKORC1-prom-G-forward	GAAAAACAACCATTGGCCG	Forward	0.24
	VKORC1-prom-A-reverse	GTGAGCCACCGCACCT	Reverse	0.16
<i>CYP2C9</i> *2	C2C9-E3-forward	AATAGTAACTTCGTTTGCTGTTATCTC	Forward	0.24
	C2C9-E3-reverse	CAGTAGAGAAGATAGTAGTCCAGTAAGGT	Reverse	0.16
	C2C9-E3-T-forward	GGAAGAGGAGCATTGAGGACT	Forward	0.16
	C2C9-E3-C-reverse	GGGCTTCCTCTTGAACACG	Reverse	0.24
<i>CYP2C9</i> *3	C2C9-E7-forward	GCCATTTTCTCCTTTTCCAT	Forward	0.2
	C2C9-E7-reverse	GGAGAACACACACTGCCAGA	Reverse	0.2
	C2C9-E7-A-forward	GCACGAGGTCCAGAGATACA	Forward	0.2
	C2C9-E7-C-reverse	TGGTGGGGAGAAGGTCAAG	Reverse	0.2

ASA = allele-specific amplification; ***CYP2C9*** = cytochrome P450 2C9; ***VKORC1*** = vitamin K epoxide reductase complex subunit 1.

Page 16, column 2, “CYP2C9*2” section, paragraph 1, lines 1–5: The following text, which previously read:

“The external forward and external reverse primers were located 446–472 bp upstream and 78–106 bp downstream of the informative SNP, respectively (figure 1b). Amplification with external forward and external reverse primers yielded a 579 bp PCR product; . . .”
has now been corrected as follows:

“The external forward and external reverse primers were located 448–474 bp upstream and 78–106 bp downstream of the informative SNP, respectively (figure 1b). Amplification with external forward and external reverse primers yielded a 581 bp PCR product; . . .”.

Page 17, column 1, paragraph 1, lines 1–3: The following text, which previously read:

“... amplification with C2C9-E3-C-reverse and external forward primers, representing the presence of a C allele, yielded a 491 bp product . . .”

has now been corrected as follows:

“... amplification with C2C9-E3-C-reverse and external forward primers, representing the presence of a C allele, yielded a 493 bp product . . .”.

Note

All print and online versions of this article have been updated to reflect these corrections.